Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors
- 1 November 1999
- journal article
- clinical trial
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 26 (8) , 877-882
- https://doi.org/10.1016/s0969-8051(99)00059-1
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3Molecular Endocrinology, 1996
- OctreotideNew England Journal of Medicine, 1996
- [111In-DTPA-D-Phe1]Octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatmentActa Endocrinologica, 1994
- Ion channels and the signal transduction pathways in the regulation of growth hormone secretionTrends in Endocrinology & Metabolism, 1994
- Somatostatin Regulates Somatostatin Receptor Subtype mRNA Expression in GH3 CellsBiochemical and Biophysical Research Communications, 1994
- Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.Journal of Clinical Investigation, 1994
- RESISTANCE OF METASTATIC PANCREATIC ENDOCRINE TUMOURS AFTER LONG‐TERM TREATMENT WITH THE SOMATOSTATIN ANALOGUE OCTREOTIDE (SMS 201–995)Clinical Endocrinology, 1989
- SomatostatinNew England Journal of Medicine, 1983
- Somatostatin: Hypothalamic Inhibitor of the Endocrine PancreasScience, 1974
- Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth HormoneScience, 1973